GRAIL, Inc. (GRAL) stock
GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$105.88+0.28 (+0.27%)
Close on Nov 17, 2026Market cap $4.73BP/E –Yield –
Grail r&d expenses
Research and development expenses are spending on new products and technology.
Grail's R&D Expenses for the twelve months ending Jun 30, 2026 was $190.99M, down 15.8% year over year. For fiscal 2025 it was $195.79M, down 39.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.79M | -39.3% |
| FY2024 | Dec 31, 2024 | $322.38M | -4.8% |
| FY2023 | Dec 31, 2023 | $338.75M | +2.8% |
| FY2022 | Jan 1, 2023 | $329.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $47.43M | +1.7% |
| Q1 FY2026 | Mar 31, 2026 | $48.02M | -10.5% |
| Q4 FY2025 | Dec 31, 2025 | $46.90M | -3.0% |
| Q3 FY2025 | Sep 30, 2025 | $48.65M | -37.8% |
| Q2 FY2025 | Jun 30, 2025 | $46.63M | -50.5% |
| Q1 FY2025 | Mar 31, 2025 | $53.63M | -47.2% |
| Q4 FY2024 | Dec 31, 2024 | $48.33M | – |
| Q3 FY2024 | Sep 30, 2024 | $78.23M | – |
| Q2 FY2024 | Jun 30, 2024 | $94.20M | – |
| Q1 FY2024 | Mar 31, 2024 | $101.63M | – |
See a number that looks wrong?